Archive for the ‘Viking Therapeutics’ Category

Viking Therapeutics

November 25th, 2015 | Posted in 2015, Viking Therapeutics

San Diego-based Viking Therapeutics, a biopharmaceutical firm, announced that it has filed an Investigational New Drug (IND) application with the FDA for a product candidate meant to treat high cholesterol and fatty liver disease. This would allow the company to start a Phase 2 trial of the product, VK2809. Viking expects to initiate the Phase 2 clinical trial […]

Viking Therapeutics

June 3rd, 2015 | Posted in 2015, Viking Therapeutics

La Jolla-based Viking Therapeutics, announced that the underwriters of its recent IPO have exercised their option to purchase an additional 450,000 shares. That brings Viking Therapeutics aggregate gross proceeds of $27.6 Million.